CHILDS JOHN W

Director John W. Childs bought 294,117 shares of MANE at $17.00 ($5.0M) amid cluster buying by 4 other insiders in 14 days.

Director John W. Childs purchased 294,117 shares at $17.00 on 2026-02-05, expanding his holdings from 1,907,889 shares to 2,202,006 shares (a +15.4% increase). This transaction is part of a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence in the company following its very recent listing (2 trading days prior to this filing). The buy price of $17.00 compares to the current market price of $37.16, establishing a baseline for monitoring whether near-term momentum persists or reverses. Note: This filing involves a conversion of derivative securities; the insider's full position may exceed the Table I holdings shown, pending Form 4 Table II population.

Director John W. Childs bought 3,333,333 shares (3.33M) of BHVN at $7.50 for $25.0M on 2025-11-13; stock now $8.27, off 83.6% from 52-week high.

John W. Childs, a director at Biohaven, purchased 3,333,333 shares at $7.50, bringing his holdings from 2,320,571 to 5,653,904 shares—a 143.6% increase in his stake. This large acquisition occurs as the stock trades down 83.6% from its 52-week high of $50.36 and has fallen 48.2% in the past 30 days. His prior trades at BHVN show a concerning pattern: 5 earlier purchases all resulted in negative 90-day returns ranging from -23.1% to -49.0%, with zero instances of profitable 90-day outcomes post-purchase. The company reported a net loss of $173,443,000 over its most recent full fiscal year, underlining fundamental challenges. A cluster of 3 other insiders also purchased within the past 14 days, suggesting coordinated or reactive positioning rather than an isolated conviction signal.

Director Childs buys 32,700 shares for $996.2K at $30.47 avg; stock -48.2% from 52-week high, 3 of 4 prior BHVN buys well-timed at 90d mark.

CHILDS JOHN W (Director) executed 4 separate purchases totaling 32,700 shares for $996,238.47 at a blended average price of $30.47 on 2025-03-04. The transaction occurred as the stock trades at $30.97, down -48.2% from its 52-week high of $59.75 and -17.9% over the past 30 days. Historically, his prior BHVN trades demonstrate a strong pattern of well-timed purchases: 3 of 4 measurable prior buys showed positive 90-day returns, including a +44.3% gain after his 2024-07-18 purchase and +15.3% and +10.6% gains after his May 2024 buys. The company reported a net loss of $160,304,000.00 in its most recent full fiscal year and carries a $3.2B market cap. The combination of a substantial acquisition at depressed price levels, convergence with his historical pattern of timely entry points at BHVN specifically, and the magnitude of the stake positions this as a noteworthy conviction signal that merits close monitoring.

Director John W. Childs bought 29,000 shares of BHVN at $35.94 on 2024-12-30 despite stock down 37.5% from 52-week high and company's $-160.3M net loss

Director John W. Childs purchased 29,000 shares at $35.94 on 2024-12-30, adding to a substantial position of 2.37M shares total. The buy occurred as BHVN traded at -37.5% from its 52-week high and -18.8% over the prior 30 days, while the company reported a full-year net income of $-160.3M. Historically, Childs's same-ticker buys at BHVN show mixed results: 3 of 5 prior purchases generated positive 90-day returns (July 2024 +44.3%, May 30 +15.3%, May 13 +10.6%), while 2 posts declines (April 2024 -12.2%, October 2024 -21.4%). His broader cross-ticker track record reflects stronger discipline: 11 prior open-market buys achieved 63.64% 90-day win rate with +26.9% average 90-day return. The current transaction's signal depends on whether this represents conviction in a turnaround or routine portfolio maintenance amid unprofitability.

Director John W. Childs bought 21,052 shares of BHVN at $47.50 for $999,970.00 on 2024-10-02; cluster buy with 2 other insiders.

Director John W. Childs purchased 21,052 shares at $47.50 on 2024-10-02, representing his first open-market accumulation at BHVN (zero prior holdings). His cross-ticker track record shows 10 prior buys with a 90d win rate of 66.67% and an average 90d return of +30.3%, though at BHVN specifically, his 4 prior measurable buys produced mixed results: 2 of 4 showed well-timed entry (positive 90d outcomes), while 2 of 4 underperformed at the 90-day mark. The current price of $46.65 is -21.9% from the 52-week high of $59.75 but +22.2% over the past 30 days and +36.9% over 90 days, indicating recent momentum recovery. Notably, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. The company remains unprofitable with a net income of $-319,771,000.00 against a market cap of $4,410,396,102.45, adding context to the director's entry decision despite negative fundamentals.

Director John W. Childs buys 28,400 BHVN shares at $35.67; cross-ticker track record shows 100% 90d win rate, but BHVN-specific prior buys all negative at 30d.

Director John W. Childs purchased 28,400 shares of Biohaven at $35.67 on 2024-07-18, adding to a substantial 2.34M share position. His cross-ticker track record across all open-market transactions shows a strong 100% win rate over 90 days with an average 90-day return of +71.0%. However, this same-ticker history at BHVN presents a contrasting picture: his five prior purchases (all in April and May 2024) have each posted negative 30-day returns ranging from -2.4% to -7.3%, with no measurable 90-day outcomes yet available. The company remains deeply unprofitable with a net loss of $-179,504,000.00 in its most recent full fiscal year. This transaction places an otherwise successful insider's recent BHVN activity in tension with his strong historical track record elsewhere.